drugset / Trial / NCT06066346
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Phase 2
Recruiting
17 enrolled
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Timeline
- Start
- 2023-09-27
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |